Navigation Links
JAK inhibitor provides rapid, durable relief for myelofibrosis patients
Date:9/15/2010

, a JAK1 and JAK2 inhibitor developed by Incyte Corp., established maximum tolerated doses and then optimal dosing regimens for the drug, which targets abnormal signaling caused by a specific mutation in the JAK2 gene that was discovered in 2005 in patients with myelofibrosis.

The clinical trial began in June 2007 at MD Anderson and the Mayo Clinic and enrolled 153 patients, all of whom had either advanced disease or were newly diagnosed with high intermediate- or high-risk myelofibrosis. Clinical responses have been maintained and 115 patients (75 percent) remain on the trial.

Most patients benefited, with those on optimal doses experiencing:

  • A median reduction in spleen volume, as measured by magnetic resonance imaging, of 33 percent at six months, with 48 percent enjoying reductions of 35 percent or higher. This equals a median reduction of 52 percent in the length of the spleen below the ribcage, measured by palpation, which is how spleen size is typically measured in clinical practice.
  • Swift and lasting spleen reduction; 70 percent to 82 percent of patients on the three optimal dosing regimens had spleen reduction of at least 25 percent that occurred within the first two months of therapy and lasted beyond a year.
  • Rapid and lasting improvement in symptom score, with 51 percent of patients achieving a 50 percent reduction at one month, and 58 percent maintaining that reduction at six months.
  • Greater exercise capacity as measured in a six-minute walk. Patients increased their distance by a median of 34 meters at one month and 71 meters at six months.
  • Median weight gain ranging from 14.5 pounds to 20.6 lbs after one year.

Symptom improvement coincided with a quick and sustained reduction in a variety of inflammatory cytokines involved in disease biology.

The main side effect is lowered blood cell counts in some patients, which can be remedied by lower doses or temporarily
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

1

GOOD

Page: 1 2 3

Related medicine news :

1. BRAF inhibitor shows promising preclinical activity against melanoma
2. Patients Who Take a Proton-Pump Inhibitor With Medicine to Prevent Blood Clots Are Less Likely to Be Hospitalized for Bleeding Ulcers
3. University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
4. Suite 101.com Provides Insight Into Consumer Reading Behavior Online
5. Ochsner Health System Connects Community Physicians to Electronic Medical Records; Orion Health HIE Solution Provides Access to Healthcare Providers Across the Gulf South
6. Pets Guardian Provides A Pet Safety System, Ensuring Pets Will Be Cared For In Case of a Personal Emergency
7. International liver cancer congress provides possible solutions to reduce significant burden
8. Principal Protected Index Investing Provides Innovative Method to Significantly Reduce Stock Market Loss and Risk
9. Progesterone is effective for hot flash treatment and provides an alternative to estrogen
10. What's The Best Whole House Water Purification System? Sweetwater LLC Provides Comparison
11. New Web Site Provides Helpful Exercise and Nutrition Tips
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 EnvirOasis, ... the contractor and ESCO market is pleased to announce ... Consortium (DLC) Listed LED products. EnvirOasis has been ... fixtures and retrofit kits and has recently brought ... LED (Light Emitting Diode) is energy efficient lighting ...
(Date:5/23/2013)... May 23 (HealthDay News) -- The sensation of itching ... traced back to a small molecule released in the ... mice. Researchers say this molecule, known as natriuretic ... the central nervous system. Ultimately, this signal is experienced ... and mice are similar, the researchers concluded that a ...
(Date:5/23/2013)... HealthDay Reporter , , THURSDAY, May 23 (HealthDay News) ... sharply, especially among Hispanic teens, according to a new government ... 15 to 19 dropped by nearly one half from 1991 ... teens to 31 births for every 1,000. From 2007 ... 25 percent, from 41.5 to about 31. During that ...
(Date:5/23/2013)... A shortage of a critical tuberculosis drug has hampered ... to contain the spread of the highly infectious lung ... was first used in 1951 and is one of ... first-line treatment for tuberculosis (TB). Patients must take the ... U.S. Centers for Disease Control and Prevention. However, ...
(Date:5/23/2013)... U.S. scientists have used virus isolated from a person ... whether the virus could infect and be transmitted between ... in influenza research, and efficient transmission of influenza virus ... the same process might occur in people. The research ... Allergy and Infectious Diseases, part of the National Institutes ...
Breaking Medicine News(10 mins):Health News:EnvirOasis Lighting Announces Energy Star and Design Lights Consortium LED Products 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:U.S. Teen Birth Rate Plummets: Report 2Health News:U.S. Teen Birth Rate Plummets: Report 3Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2Health News:Ferrets, pigs susceptible to H7N9 avian influenza virus 2
... the No. 1 line-item cost of Medicare reimbursement and affects ... which can have devastating effects on the eye, affect 42 ... 80, and 68 percent of the population over the age ... University of Missouri professor has identified an important step in ...
... As millions of emails by,faithful Christians circulate around ... weeping image of Jesus Christ at Florida Hospital,s ... an explanation,today: "Jesus was weeping at the deplorable ... billion-dollar religious hospital,operation run by millionaire executives that ...
... effectiveness , , THURSDAY, April 17 (HealthDay News) -- The ... cells to their more plastic youthful condition in animal ... a possible new explanation for the antidepressant activity of ... it could be used to treat other conditions caused ...
... Dr. Thomas Gamba of Philadelphia to continue PDA,s efforts to improve ... ... Pennsylvania Dental,Association (PDA) recently installed Dr. Thomas W. Gamba of Philadelphia as,its ... improving patient access to oral health services will continue,to be a major ...
... MD, DrPH, Anna Cheskis Gelman and Murray Charles Gelman ... the Mailman School of Public Health and professor of ... 2008 Distinguished Investigator Award from NARSAD, the world,s leading ... Susser was selected for a study on famine and ...
... Celebrate Exemplary Nurses Who Support Chicagoland,s Medically ... when Sally Lemke lost,her nursing job providing prenatal care ... felt like a super star. That,s because the week,before ... her commitment and,passion for community health nursing and named ...
Cached Medicine News:Health News:MU researchers find clue to cataract formation 2Health News:Weeping Image of Jesus at Florida Hospital Explained 2Health News:Prozac Makes Old Brain Cells Young 2Health News:Prozac Makes Old Brain Cells Young 3Health News:New Pennsylvania Dental Association President Will Focus on Improving Access to Care 2Health News:New Pennsylvania Dental Association President Will Focus on Improving Access to Care 3Health News:Ezra Susser, MD, DrPH, receives Distinguished Investigator Award from NARSAD 2Health News:Chicagoland Super Star Community and Public Health Nurses - Now Is Your Chance to Win $25,000 2Health News:Chicagoland Super Star Community and Public Health Nurses - Now Is Your Chance to Win $25,000 3
(Date:5/23/2013)...  Hologic, Inc. (Hologic or the Company) (NASDAQ: ... and supplier of premium diagnostics, medical imaging systems ... the healthcare needs of women, today announced that ... clinical practice comparing breast cancer screening with Hologic,s ... mammography alone showed a significant reduction in recall ...
(Date:5/23/2013)... 23, 2013  BioElectronics Corporation (OTC Pink: BIEL), the ... on the FDA panel meeting for non-thermal shortwave diathermy: ... Pulsed Shortwave Therapy Meeting was held on May 21, ... The focus of the meeting was very narrow, in ... solely on the application of non-thermal shortwave diathermy for ...
(Date:5/23/2013)... YORK , May 23, 2013  Intercept Pharmaceuticals, ... stage biopharmaceutical company focused on the development and commercialization ... diseases, such as primary biliary cirrhosis, today announced that ... Chief Executive Officer, will present at the Deutsche Bank ... Boston on Wednesday, May 29, 2013 at ...
Breaking Medicine Technology:First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 2First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 3First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection 4BioElectronics and Pulsed Shortwave Therapy Make Progress 2
... Significant Improvement in Cognitive Performance and Global Clinical Status ... ... 30 Forest Laboratories, Inc.,(NYSE: FRX ) presented today positive ... at the 2008,Alzheimer,s Association International Conference on Alzheimer,s Disease,(ICAD). The study ...
... 30 Wound Care Innovations, LLC,a subsidiary of ... today an evidence based study with a NE ... wound care collagen,product, CellerateRx(R), on diabetic venous ulcers. ... Control and Prevention, diabetes now,affects nearly 24 million ...
Cached Medicine Technology:New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 2New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 3New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation 4Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers 2
... the world leader in peel-away introducers. ... for permanent pacemaker and defibrillator lead ... implantation, and for temporary pacemaker insertions. ... Medical Peel-Away introducers includes the Di-Lock™ ...
The RX HERCULINK® PLUS Biliary Stent System is Guidant's high performance .014" guide wire compatible system. It is available in stent diameters of 4.0-6.5mm for the 12mm stent length and 4.0-7.0...
... Supreme and Response catheters comprise the ... available for electrophysiology procedures. Their advanced ... for superior torque response with a ... curves and French sizes, Supreme and ...
... Supreme and Response catheters comprise the ... available for electrophysiology procedures. Their advanced ... for superior torque response with a ... curves and French sizes, Supreme and ...
Medicine Products: